Analyse produit facultative
Avec votre autorisation, nous utilisons une analyse limitée et respectueuse de la vie privée pour comprendre les parcours de recherche utiles. Nous n’utilisons ni traceurs publicitaires ni enregistrement de session. Vous pouvez modifier ce choix dans les préférences. Consultez la Politique de confidentialité.
Illumina, Inc.'s published Sell conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $39.1B | |
|---|---|---|
| Revenue (ttm) | 4.5B | |
| Net income (ttm) | 824M | |
| EPS (ttm) | $5.37 | |
| Shares out | 151M | |
| P/E (trailing) | 53.8x | |
| P/E (forward) | 40.3x | |
| Volume | 2,029,934 | |
| Beta | 1.42 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2022-01-02 | 2023-01-01 | 2023-12-31 | 2024-12-29 | 2025-12-28 | Trend |
| Revenue | $4.53B | $4.58B | $4.50B | $4.37B | $4.34B | -1.0% |
| Gross profit | $3.15B | $2.97B | $2.74B | $2.86B | $2.87B | -2.3% |
| Operating income | $-123.0M | $-4.18B | $-1.07B | $-833.0M | $807.0M | — |
| Net income | $762.0M | $-4.40B | $-1.16B | $-1.22B | $850.0M | +2.8% |
| EPS (diluted) | $4.90 | $-28.00 | $-7.34 | $-7.69 | $5.45 | +2.7% |
| EBITDA | $128.0M | $-3.79B | $-1.07B | $-725.0M | $1.46B | +83.7% |
| R&D | $1.19B | $1.32B | $1.35B | $1.17B | $967.0M | -5.0% |
| SG&A | $2.09B | $1.30B | $1.61B | $1.09B | $1.09B | -15.1% |
Recent company headlines from major financial publishers.
The modal base path reflects management's FY2026 guidance for reported revenue and operating margin. Clinical consumables expansion at mid-teens offsets mid-to-high single-digit research declines. This trajectory generates Fair value of $119.53, implying -53.9% return relative to $259.19.
In the Bull case, clinical sequencing expands rapidly across oncology and rare disease diagnostics, driving mid-teens clinical consumables growth and enabling FY2027 revenue to reach high single digits. Operating margins expand via high consumable pull-through, supporting Potential value of $146.73. Notably, even this optimistic outcome remains well below $259.19.
| Ke ↓ / g → | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |
|---|---|---|---|---|---|
| 9.3% | $122 | $124 | $127 | $129 | $132 |
| 9.8% | $119 | $121 | $123 | $125 | $127 |
| 10.3% | $116 | $118 | $120 | $121 | $124 |
| 10.8% | $114 | $115 | $117 | $118 | $120 |
| 11.3% | $111 | $113 | $114 | $115 | $117 |
Upcoming earnings date and setup when available.
La notation portée par l'édition de recherche publiée chaque mois. Une notation compare le cours à la date d'analyse à la juste valeur ; elle n'indique pas si l'appréciation s'est révélée juste.
| Année | janv. | févr. | mars | avr. | mai | juin | juil. | août | sept. | oct. | nov. | déc. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
